A Phase 4 interventional study of Celecoxib and Placebo in Arthroscopy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Celecoxib
Other: Placebo
400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
Matched placebo
Total analgesic use after surgery
Time frame: 24 hours
Physical examination
Time frame: Day 7
Number and percentage of subjects taking analgesic (hydrocodone bitartrate 5 mg/acetaminophen 500 mg [HC/APAP]) after surgery
Time frame: 1, 2, 6, 8, 10, 12, 24, and 36 hours
Time to analgesic use after surgery
Time frame: 1, 2, 6, 8, 10, 12, 24, and 36 hours
Cumulative number of HC/APAP tablets taken after first dose of study medication
Time frame: 1, 2, 6, 8, 10, 12, 36 hours and Day 2
Vital signs
Time frame: Day 7
Patient's Assessment of Knee Pain, according to visual analogue scale at rest and with movement after surgery
Time frame: 1, 2, 6, 8, 10, 12, 24 and 36 hours
Change in volumetric measurement of both knees from prior to surgery
Time frame: Day 7
Patient Treatment Satisfaction Scales after surgery
Time frame: 24 hours
Adverse events
Time frame: Day 7
The record gives a start of Feb 2003 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →